Research — Comparative Analysis

Retatrutide vs Semaglutide vs Tirzepatide: Dosage Comparison

By Dr. Nadia Haroun, PharmD · Research Director · April 2026

28.7%

Retatrutide (12 mg)

22.5%

Tirzepatide (15 mg)

16.9%

Semaglutide (2.4 mg)

Compounds Compared

Dr. Nadia Haroun, PharmD · Published April 2, 2026 · Phase 3 trial data (TRIUMPH-4 · SURMOUNT-1 · STEP 1)

Fact-checked · Reviewed by Dr. Nadia Haroun, PharmD

TL;DR — Verdict

Retatrutide is a triple-agonist (GLP-1/GIP/GCGR) dosed 2–12 mg/week, semaglutide is a GLP-1 agonist dosed 0.25–2.4 mg/week, and tirzepatide is a dual-agonist (GLP-1/GIP) dosed 2.5–15 mg/week. All three are administered once weekly via subcutaneous injection. Retatrutide showed the highest weight reduction in clinical trials—28.7% in TRIUMPH-4—compared to tirzepatide (22.5% in SURMOUNT-1) and semaglutide (16.9% in STEP 1). Cross-trial comparisons have inherent limitations due to differences in study populations, endpoints, and durations. For research use only.

RESEARCH SUPPLY

Need Research-Grade Retatrutide?

Janoshik-verified, HPLC ≥99.2% purity. Retatrutide Pen 30 mg from AED 1,500/pen. Ships from Dubai.

Order Now →

View Product Details → Retatrutide Dosage Calculator → See COA →

Mechanism of Action Comparison

The three compounds compared in this analysis differ fundamentally in their receptor pharmacology. Understanding these mechanistic differences is essential for interpreting dosage requirements and clinical outcomes.

Retatrutide (LY3437943) — Triple Agonist

Retatrutide is the first triple hormone receptor agonist to reach Phase 3 clinical development. It simultaneously activates three metabolic receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and the glucagon receptor (GCGR). The GLP-1 component suppresses appetite and slows gastric emptying. The GIP receptor agonism enhances insulin secretion and may buffer GLP-1-mediated gastrointestinal effects. The GCGR component increases hepatic energy expenditure and fat oxidation—a mechanism absent from both semaglutide and tirzepatide.^[1]

Semaglutide (Ozempic/Wegovy) — Single GLP-1 Agonist

Semaglutide is a selective GLP-1 receptor agonist with a long half-life engineered through albumin binding and fatty acid acylation. It acts on a single receptor pathway—GLP-1—to reduce appetite, slow gastric emptying, and improve glycaemic control. Semaglutide has received FDA approval for type 2 diabetes (Ozempic, 0.5–2 mg) and chronic weight management (Wegovy, 2.4 mg).^[3]

Tirzepatide (Mounjaro/Zepbound) — Dual GLP-1/GIP Agonist

Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors. The addition of GIP receptor activation enhances insulin sensitivity and may provide a complementary weight-reduction mechanism to GLP-1 agonism alone. Tirzepatide has received FDA approval for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).^[2]

The key pharmacological distinction: retatrutide’s glucagon receptor component drives additional energy expenditure through hepatic fat oxidation—a mechanism not present in either semaglutide or tirzepatide. This triple-agonist approach is hypothesised to explain the higher weight-reduction outcomes observed in clinical trials. For a detailed comparison of semaglutide and other GLP-1 agents, see our semaglutide comparison analysis.

Dosage Range Comparison

The table below provides a side-by-side comparison of dosage parameters for all three compounds based on published clinical trial protocols and approved prescribing information.

Dosage Parameters — Side-by-Side Comparison

Parameter	Retatrutide	Semaglutide	Tirzepatide
Starting Dose	2 mg	0.25 mg	2.5 mg
Maximum Dose	12 mg	2.4 mg	15 mg
Dose Increments	2→4→8→12 mg	0.25→0.5→1.0→1.7→2.4 mg	2.5→5→7.5→10→12.5→15 mg
Escalation Interval	4 weeks per step	4 weeks per step	4 weeks per step
Frequency	Once weekly	Once weekly	Once weekly
Route	Subcutaneous injection	Subcutaneous injection	Subcutaneous injection
Administration Device	Pre-filled pen (investigational)	Pre-filled pen (approved)	Pre-filled pen (approved)
Receptor Targets	GLP-1 + GIP + GCGR	GLP-1	GLP-1 + GIP

Note: Retatrutide dosing reflects the TRIUMPH Phase 3 trial protocol. Semaglutide dosing reflects the Wegovy (weight management) label. Tirzepatide dosing reflects the Zepbound (weight management) label. All three compounds share the same 4-week escalation interval, but the number of titration steps differs. For detailed retatrutide dosing protocols, see the retatrutide dosage guide. Use our dosage calculator for precise measurements.

Titration Schedule Comparison

All three compounds use gradual dose escalation to improve gastrointestinal tolerability. Below are the standard titration timelines from their respective clinical programs.

Retatrutide Titration (~17 Weeks to Maximum Dose)

Weeks 1–4: 2 mg once weekly (starting dose)
Weeks 5–8: 4 mg once weekly
Weeks 9–12: 8 mg once weekly
Week 13+: 12 mg once weekly (maintenance dose)

The TRIUMPH Phase 3 protocol uses a 2 mg starting dose with 4-week escalation intervals. Phase 2 data demonstrated that this slow-titration approach reduced nausea incidence by 30–50% compared to rapid-escalation cohorts. For the full titration protocol, see our retatrutide dosage guide.

Semaglutide Titration (~16 Weeks to Maximum Dose)

Weeks 1–4: 0.25 mg once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17+: 2.4 mg once weekly (maintenance dose)

Semaglutide has the most dose increments (5 steps) but reaches maintenance in approximately 16 weeks. The Wegovy label recommends maintaining each dose for at least 4 weeks before escalation.^[3]

Tirzepatide Titration (~20 Weeks to Maximum Dose)

Weeks 1–4: 2.5 mg once weekly
Weeks 5–8: 5 mg once weekly
Weeks 9–12: 7.5 mg once weekly
Weeks 13–16: 10 mg once weekly
Weeks 17–20: 12.5 mg once weekly
Week 21+: 15 mg once weekly (maintenance dose)

Tirzepatide has the longest titration period (6 steps, ~20 weeks) and the widest dose range (2.5–15 mg). The Zepbound label notes that the maintenance dose may be individualised at 10, 12.5, or 15 mg depending on tolerability and response.^[2]

Dosing Full retatrutide titration protocol with dose-by-dose Phase 2 and Phase 3 data →

Clinical Outcomes

The following table summarises the primary weight-reduction outcomes from the pivotal Phase 3 trials for each compound. These are the most commonly cited headline efficacy figures.

Weight Reduction Outcomes — Phase 3 Pivotal Trials

Parameter	Retatrutide	Tirzepatide	Semaglutide
Trial	TRIUMPH-4	SURMOUNT-1	STEP 1
Mean Weight Reduction	28.7%	22.5%	16.9%
Dose (Max Arm)	12 mg	15 mg	2.4 mg
Trial Duration	48 weeks	72 weeks	68 weeks
Population	Adults with obesity	Adults with obesity	Adults with obesity
Phase	Phase 3 (topline)	Phase 3 (published)	Phase 3 (published)
Mechanism	Triple (GLP-1/GIP/GCGR)	Dual (GLP-1/GIP)	Single (GLP-1)
Regulatory Status	Investigational	FDA approved (Zepbound)	FDA approved (Wegovy)

Cross-trial comparison limitations: These outcomes are from separate clinical trials with different study populations, baseline characteristics, trial durations, and statistical endpoints. Direct head-to-head comparisons would require a randomised controlled trial evaluating all three compounds simultaneously—no such trial has been conducted to date. Retatrutide TRIUMPH-4 data are topline results; full published data are expected in 2026.^[1]^[4]

Several factors make cross-trial weight-reduction comparisons imprecise:

Trial duration: TRIUMPH-4 ran for 48 weeks, while SURMOUNT-1 and STEP 1 ran for 72 and 68 weeks respectively. Weight loss may not have fully plateaued at 48 weeks in the retatrutide arm
Baseline BMI: Mean baseline BMI differed across trials, which affects the magnitude of percentage weight loss
Concomitant interventions: Diet and exercise counselling protocols varied between trial programs
Publication status: TRIUMPH-4 results are topline only (December 2025); full peer-reviewed data with subgroup analyses are pending

Despite these caveats, the trend is consistent across Phase 2 and Phase 3 data: triple-agonist retatrutide produces numerically greater mean weight reduction than dual-agonist tirzepatide, which in turn produces greater mean weight reduction than single-agonist semaglutide. The magnitude of this difference is broadly consistent with the increasing number of receptor pathways engaged.

Which Compound Is Right for Your Research?

The choice between these three compounds in a research context depends on the specific study objectives, available infrastructure, and the regulatory landscape relevant to the research setting.

For maximum weight-reduction data: Retatrutide’s triple-agonist mechanism has produced the highest weight-reduction figures of any incretin-based compound studied to date. Researchers focused on the upper bounds of pharmacological weight reduction may find retatrutide most relevant
For established safety and efficacy data: Semaglutide and tirzepatide have both completed their full Phase 3 programs and received regulatory approval. Published long-term safety data, cardiovascular outcome trial results (SELECT for semaglutide), and real-world evidence are available for both
For mechanism-of-action studies: Retatrutide’s glucagon receptor component enables research into GCGR-mediated energy expenditure, hepatic fat metabolism, and the interplay between three receptor pathways—questions that cannot be studied with single- or dual-agonist compounds
For comparative studies: Researchers designing protocols that compare incretin-based therapies should account for differences in dose ranges, titration timelines, and the lack of standardised head-to-head trial data

Retatrutide remains an investigational compound not yet approved by any regulatory authority. All research involving retatrutide should be conducted under appropriate oversight and compliance frameworks. For a broader comparison that includes additional pipeline compounds, see our retatrutide vs tirzepatide vs CagriSema analysis.

Frequently Asked Questions

Which is more effective — retatrutide or semaglutide?

In clinical trials, retatrutide produced greater mean weight reduction than semaglutide—28.7% (TRIUMPH-4, 12 mg, 48 weeks) vs 16.9% (STEP 1, 2.4 mg, 68 weeks). However, cross-trial comparisons have limitations due to differences in study populations, trial duration, and endpoints. Retatrutide is an investigational compound not yet approved by any regulatory authority.

Can you switch between retatrutide, semaglutide, and tirzepatide?

Switching between incretin-based compounds is a clinical decision that should be guided by a healthcare provider. There is currently no published clinical trial data on direct switching protocols between retatrutide and other GLP-1 or dual-agonist compounds. Washout periods and re-titration may be required depending on the compounds involved.

Why does retatrutide have higher dose numbers than semaglutide?

Dose numbers reflect molecular potency, not efficacy. Semaglutide is active at microgram-to-low-milligram levels due to its high receptor binding affinity, while retatrutide requires higher milligram doses to achieve its triple-agonist effect across GLP-1, GIP, and glucagon receptors. A higher dose number does not mean a stronger or more dangerous compound.

Do all three compounds have the same side effects?

All three share gastrointestinal side effects (nausea, diarrhea, vomiting) as the most common adverse events, consistent with the GLP-1 receptor agonist class. However, the specific rates and profiles differ—retatrutide’s glucagon receptor component may produce distinct metabolic effects, and tirzepatide’s GIP agonism may buffer some GI symptoms. For full side effect data, see our retatrutide side effects breakdown.

Is retatrutide FDA approved?

No. As of April 2026, retatrutide has not been approved by the FDA or any other regulatory authority. It remains an investigational compound in Phase 3 clinical trials (TRIUMPH program). Semaglutide (Wegovy) and tirzepatide (Zepbound) have both received FDA approval for chronic weight management.

How do I calculate the correct dose for any of these compounds?

Dosing should follow the titration schedules established in clinical trials for each compound. For retatrutide specifically, our reconstitution calculator can help researchers determine precise measured amounts based on concentration and pen specifications. Always consult published trial protocols and a qualified researcher or healthcare provider for dosing guidance.

Our Research Standards

This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →

About the Author

Dr. Nadia Haroun, PharmD

Research Director, Remy Peptides

Dr. Haroun leads editorial review across all research articles covering GLP-1 receptor agonists, triple agonists, and the obesity drug pipeline. Her work spans peptide analytical chemistry, HPLC purity validation, and clinical trial data interpretation.

View editorial policy →

References & Citations

Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340. doi:10.1056/NEJMoa2206038
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
Eli Lilly and Company. Lilly’s retatrutide (LY3437943) met primary endpoint in TRIUMPH-4 Phase 3 obesity trial. Press release, December 11, 2025.
Eli Lilly. TRIUMPH Clinical Trial Program for Retatrutide — Phase 3 Design. ClinicalTrials.gov.
Novo Nordisk. Wegovy (semaglutide) Prescribing Information. FDA approved June 2021.

ORDER

Retatrutide Pen 30 mg

99.262% HPLC purity, Janoshik Analytical. 300 clicks per pen, ships from Dubai.

Order Retatrutide Pen →